The therapeutic potential of nanoscale sphingolipid technologies

Jody L. Hankins, Ushma A. Doshi, Jeremy K. Haakenson, Megan M. Young, Brian M. Barth, Mark Kester

Research output: Chapter in Book/Report/Conference proceedingChapter

9 Scopus citations


Nanotechnologies, while small in size, widen the scope of drug delivery options for compounds with problematic pharmacokinetics, such as bioactive sphingolipids. We describe the development of historical sphingolipid nanotechnologies, such as nanoliposomes, and project future uses for a broad repertoire of nanoscale sphingolipid therapy formulations. In particular, we describe sphingo-nanotherapies for treatment of cancer, inflammatory disease, and cardiovascular disease. We conclude with a discussion of the challenges associated with regulatory approval, scale-up, and development of these nanotechnology therapies for clinical applications.

Original languageEnglish (US)
Title of host publicationSphingolipids
Subtitle of host publicationBasic Science and Drug Development
PublisherSpringer Science and Business Media, LLC
Number of pages14
ISBN (Print)9783709113677
StatePublished - 2013

Publication series

NameHandbook of Experimental Pharmacology
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'The therapeutic potential of nanoscale sphingolipid technologies'. Together they form a unique fingerprint.

Cite this